UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cel… Read more
UnicoCell Biomed Co., Ltd. (6794) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.066x
Based on the latest financial reports, UnicoCell Biomed Co., Ltd. (6794) has a cash flow conversion efficiency ratio of -0.066x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-49.47 Million) by net assets (NT$750.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
UnicoCell Biomed Co., Ltd. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how UnicoCell Biomed Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
UnicoCell Biomed Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UnicoCell Biomed Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zenix Robotics Co.,Ltd
KQ:381620
|
-0.075x |
|
Alpha Technology Group Limited Ordinary Shares
NASDAQ:ATGL
|
-0.326x |
|
Korea Parts & Fasteners Co.Ltd
KQ:024880
|
0.085x |
|
Betmakers Technology Group Ltd
PINK:TPBTF
|
-0.076x |
|
Insights Analytics Bhd
KLSE:0376
|
N/A |
|
Global View Co Ltd
TW:3040
|
-0.005x |
|
Big Shopping Centers Ltd
TA:BIG
|
0.014x |
|
Tamil Nadu Newsprint & Papers Limited
NSE:TNPL
|
-0.025x |
Annual Cash Flow Conversion Efficiency for UnicoCell Biomed Co., Ltd. (2017–2024)
The table below shows the annual cash flow conversion efficiency of UnicoCell Biomed Co., Ltd. from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$684.61 Million | NT$-61.52 Million | -0.090x | +18.23% |
| 2023-12-31 | NT$596.44 Million | NT$-65.55 Million | -0.110x | +42.32% |
| 2022-12-31 | NT$333.85 Million | NT$-63.60 Million | -0.191x | +18.80% |
| 2021-12-31 | NT$263.00 Million | NT$-61.71 Million | -0.235x | +12.57% |
| 2020-12-31 | NT$343.41 Million | NT$-92.16 Million | -0.268x | -2.35% |
| 2019-12-31 | NT$294.32 Million | NT$-77.17 Million | -0.262x | -23.38% |
| 2018-12-31 | NT$272.98 Million | NT$-58.01 Million | -0.213x | +31.17% |
| 2017-12-31 | NT$137.33 Million | NT$-42.40 Million | -0.309x | -- |